Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guard3: AVR-RD-02 for Gaucher Disease Type 3
NCT05815004Phase 3Withdrawn
- Sponsor
- AVROBIO, Inc.
- Start
- Oct 2023
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, Lentiviral Vectors
01
Overview
A Phase 3 trial of AVR-RD-02 in Gaucher disease type 3, sponsored by AVROBIO, Inc.. Planned start Oct 2023; status: withdrawn.
02
Drugs
AVR-RD-02
03
Conditions
Gaucher disease type 3
Beyond the preview
Go deeper on NCT05815004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05815004.